HK1205188A1 - Process for making recombinant antidote to factor xa inhibitor xa - Google Patents
Process for making recombinant antidote to factor xa inhibitor xaInfo
- Publication number
- HK1205188A1 HK1205188A1 HK15105733.4A HK15105733A HK1205188A1 HK 1205188 A1 HK1205188 A1 HK 1205188A1 HK 15105733 A HK15105733 A HK 15105733A HK 1205188 A1 HK1205188 A1 HK 1205188A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- inhibitor
- factor
- making recombinant
- recombinant antidote
- antidote
- Prior art date
Links
- 229940123583 Factor Xa inhibitor Drugs 0.000 title 1
- 239000000729 antidote Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21006—Coagulation factor Xa (3.4.21.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261598694P | 2012-02-14 | 2012-02-14 | |
PCT/US2013/025985 WO2013123087A1 (en) | 2012-02-14 | 2013-02-13 | Process for making recombinant antidote to factor xa inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1205188A1 true HK1205188A1 (en) | 2015-12-11 |
Family
ID=47755035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15105733.4A HK1205188A1 (en) | 2012-02-14 | 2015-06-16 | Process for making recombinant antidote to factor xa inhibitor xa |
Country Status (8)
Country | Link |
---|---|
US (6) | US20130230901A1 (xx) |
EP (1) | EP2814955A1 (xx) |
JP (1) | JP2015507929A (xx) |
KR (1) | KR20140131957A (xx) |
CN (1) | CN104254603A (xx) |
HK (1) | HK1205188A1 (xx) |
IL (1) | IL234073A0 (xx) |
WO (1) | WO2013123087A1 (xx) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2453910B1 (en) * | 2009-07-15 | 2016-08-31 | Portola Pharmaceuticals, Inc. | Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding |
US20140346397A1 (en) | 2012-12-27 | 2014-11-27 | Portola Pharmaceuticals, Inc. | Compounds and methods for purification of serine proteases |
US9200268B2 (en) | 2012-12-27 | 2015-12-01 | Portola Pharmaceuticals, Inc. | Compounds and methods for purification of serine proteases |
FR3064917A1 (fr) * | 2017-04-07 | 2018-10-12 | Universite Grenoble Alpes | Facteur x mute |
JP2021527435A (ja) * | 2018-06-19 | 2021-10-14 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 第Xa因子阻害剤に対する解毒剤 |
JP2022543302A (ja) * | 2019-08-08 | 2022-10-11 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 第xa因子及び誘導体を調製するための組成物及び方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4818700A (en) | 1985-10-25 | 1989-04-04 | Phillips Petroleum Company | Pichia pastoris argininosuccinate lyase gene and uses thereof |
US4812405A (en) | 1986-02-18 | 1989-03-14 | Phillips Petroleum Company | Double auxotrophic mutants of Pichia pastoris and methods for preparation |
US4929555A (en) | 1987-10-19 | 1990-05-29 | Phillips Petroleum Company | Pichia transformation |
US5583107A (en) | 1990-09-04 | 1996-12-10 | Cor Therapeutics, Inc. | Agents affecting thrombosis and hemostasis |
JP4236698B2 (ja) * | 1990-11-26 | 2009-03-11 | ジェネティックス インスティチュート,リミテッド ライアビリティ カンパニー | 宿主細胞でのpaceの発現およびその使用法 |
US5955349A (en) | 1996-08-26 | 1999-09-21 | Zymogenetics, Inc. | Compositions and methods for producing heterologous polypeptides in Pichia methanolica |
JPH09295945A (ja) * | 1996-04-30 | 1997-11-18 | Hoechst Yakuhin Kogyo Kk | 成熟型骨誘導因子の製造方法 |
US5736383A (en) | 1996-08-26 | 1998-04-07 | Zymogenetics, Inc. | Preparation of Pichia methanolica auxotrophic mutants |
AT405740B (de) * | 1996-12-13 | 1999-11-25 | Immuno Ag | Von willebrand-faktor-derivat sowie ein verfahren zur isolierung von proteinen |
AT405517B (de) * | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-deletionsmutanten und analoge davon |
US5888809A (en) * | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
US6258559B1 (en) | 1999-03-22 | 2001-07-10 | Zymogenetics, Inc. | Method for producing proteins in transformed Pichia |
EP1728798A1 (en) * | 2005-06-01 | 2006-12-06 | ZLB Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
JP5526332B2 (ja) * | 2005-12-21 | 2014-06-18 | シーエヌジェイ ホールディングス,インコーポレイテッド | 組み換え法によって生物活性ビタミンk依存性タンパク質を製造する方法 |
SG185263A1 (en) | 2007-09-28 | 2012-11-29 | Portola Pharm Inc | Antidotes for factor xa inhibitors and methods of using the same |
KR101507718B1 (ko) * | 2008-06-24 | 2015-04-10 | 체에스엘 베링 게엠베하 | 연장된 생체내 반감기를 갖는 인자 viii, 폰 빌레브란트 인자 또는 이들의 복합체 |
WO2010117729A1 (en) | 2009-03-30 | 2010-10-14 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same |
EP2453910B1 (en) * | 2009-07-15 | 2016-08-31 | Portola Pharmaceuticals, Inc. | Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding |
-
2013
- 2013-02-13 US US13/766,652 patent/US20130230901A1/en not_active Abandoned
- 2013-02-13 CN CN201380012568.9A patent/CN104254603A/zh active Pending
- 2013-02-13 EP EP13706859.9A patent/EP2814955A1/en not_active Withdrawn
- 2013-02-13 WO PCT/US2013/025985 patent/WO2013123087A1/en active Application Filing
- 2013-02-13 JP JP2014557747A patent/JP2015507929A/ja active Pending
- 2013-02-13 KR KR1020147025409A patent/KR20140131957A/ko not_active Application Discontinuation
-
2014
- 2014-08-11 IL IL234073A patent/IL234073A0/en unknown
-
2015
- 2015-06-16 HK HK15105733.4A patent/HK1205188A1/xx unknown
- 2015-06-22 US US14/745,901 patent/US20150376592A1/en not_active Abandoned
-
2016
- 2016-12-27 US US15/391,020 patent/US20170240879A1/en not_active Abandoned
-
2018
- 2018-09-11 US US16/127,864 patent/US20190127720A1/en not_active Abandoned
-
2021
- 2021-07-28 US US17/387,806 patent/US20220098565A1/en not_active Abandoned
-
2023
- 2023-03-22 US US18/188,043 patent/US20230383276A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2015507929A (ja) | 2015-03-16 |
US20150376592A1 (en) | 2015-12-31 |
US20130230901A1 (en) | 2013-09-05 |
US20230383276A1 (en) | 2023-11-30 |
US20190127720A1 (en) | 2019-05-02 |
IL234073A0 (en) | 2014-09-30 |
US20170240879A1 (en) | 2017-08-24 |
WO2013123087A1 (en) | 2013-08-22 |
EP2814955A1 (en) | 2014-12-24 |
KR20140131957A (ko) | 2014-11-14 |
CN104254603A (zh) | 2014-12-31 |
US20220098565A1 (en) | 2022-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1210144A1 (en) | New indanyloxydihydrobenzofuranylacetic acids | |
EP2890672A4 (en) | NEW PROCESS | |
EP2867189A4 (en) | PROCESS FOR PRODUCING ACRYLATE | |
EP2750635A4 (en) | REFERENCE TO RELATED APPLICATIONS | |
SG11201401321WA (en) | Crosslinkable composition | |
PL2764038T3 (pl) | Sieciowalna kompozycja | |
ZA201400114B (en) | Can manufacture | |
GB201103499D0 (en) | Process | |
GB201107072D0 (en) | Process | |
HK1205188A1 (en) | Process for making recombinant antidote to factor xa inhibitor xa | |
GB201101370D0 (en) | Process | |
GB201107073D0 (en) | Process | |
HK1209760A1 (en) | Method for purification of recombinant factor xa derivatives xa | |
PL2888228T3 (pl) | Inhibitory oddziaływania CD40-TRAF6 | |
HK1214601A1 (zh) | 用於製造 -標記物的新型雙-銥-配合物 | |
EP2722365A4 (en) | COMPOSITION HAVING HIGH REFRACTION | |
PL2914574T3 (pl) | Nowy sposób | |
GB201115218D0 (en) | Novel process | |
GB201118334D0 (en) | Novel dosage form | |
GB201103092D0 (en) | Process | |
EP2855401A4 (en) | PREPARATION OF BN COMPOUNDS | |
GB201105537D0 (en) | New process | |
SG11201504570SA (en) | Process for transitioning | |
GB2507762B (en) | Improvements to dartboards | |
GB201116252D0 (en) | Novel process |